EchoGo Amyloidosis vs Rhythm360
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
EchoGo Amyloidosis is an AI-powered diagnostic screening tool specifically designed for the early detection of cardiac amyloidosis from echocardiogram video clips. In contrast, Rhythm360 is a broader AI-powered platform that unifies cardiac monitoring data from various devices to provide actionable insights for hypertension, heart failure, and rhythm management. While both leverage AI in cardiology, EchoGo focuses on a specific diagnostic aid, whereas Rhythm360 offers comprehensive patient management and monitoring.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is an FDA-cleared AI-powered screening tool designed to aid in the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. Rhythm360 is an AI-powered integrated platform that unifies cardiac monitoring data from various devices to provide actionable insights for hypertension, heart failure, and rhythm management, aiming to reduce alert fatigue.
EchoGo Amyloidosis analyzes echocardiogram video clips to identify suspected cardiac amyloidosis by examining echocardiographic markers such as ventricular volume, cardiac function, and myocardial movement. It integrates seamlessly with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7. Rhythm360 aggregates vendor-neutral cardiac monitoring data from all major OEMs (e.g., Medtronic, Boston Scientific, Abbott, Biotronik) and integrates bi-directionally with major EHR systems like Epic, Cerner, and Athenahealth, using AI for data normalization via API, HL7, XML, and PDF parsing.
EchoGo Amyloidosis is FDA-cleared as an AI-powered screening tool for cardiac amyloidosis and has received Breakthrough Device designation from the FDA. Rhythm360 is a HIPAA-compliant cloud-based SaaS platform and has a Business Associate Agreement (BAA).
EchoGo Amyloidosis has specific Medicare-covered codes: NTAP Code ICD-10 XXE2X19 for inpatient analysis ($1,000 per analysis) and HCPCS Code C9786 (Clinical APC Code 574) for outpatient analysis ($285 per analysis), which is covered by Medicare and select commercial insurers. Rhythm360 automates CPT code documentation and billing for services such as 93298, 93299, 99453, 99454, and 99457, and offers a flexible pricing model that scales with clinic size and platform usage.
EchoGo Amyloidosis offers high diagnostic accuracy for cardiac amyloidosis, with 85% sensitivity and 93% specificity, and consistent performance across CA subtypes. Rhythm360 improves clinical efficiency by providing AI-driven alert triage, which can lead to 80% faster response times and a reduction in alert fatigue, and includes predictive algorithms for heart failure management.
EchoGo Amyloidosis primarily focuses on its AI-powered analysis of echocardiogram video clips for cardiac amyloidosis detection. Rhythm360 offers optional 24/7/365 oversight by certified cardiac technicians (CCTs), a HIPAA-compliant mobile application for clinicians, and comprehensive remote patient monitoring services for chronic conditions.